Categories
Change Password!
Reset Password!
Following
the effective of Favipiravir
for COVID-19, RDIF to invest in drugs
based on Favipiravir.
Kirill Dmitriev, the Chief Executive Officer of Russian Direct Investment Fund (RDIF) announced on 25th June, 2020 about its prospects of financing more Favipiravir-based drugs.
He stated, “Two more pharmaceuticals are settling the clinical trials of favipiravir-based drugs in Russia which will effectively produce favipiravir-based drugs. We support those companies and plan to invest its production for these medicines.” Clinical trials of Favipiravir are presently ongoing throughout the world; especially a leading pharma company of India has already obtained registration, while Turkey is undertaking registration now, CEO told. Earlier in June, the first Favipiravir-based drug, Avifavir by RDIF and ChemRar Group has been approved for COVID-19 treatment with high efficiency in clinical trials. With its delivery in Russian hospitals initiated on 11, June, its test batches have also been delivered to Belarus.
Russia intends to invest in the production of two more drugs based on favipiravir
Comments (0)